

TECHNOLOGY BRIEF | NO. MST-209

LC/MS – Clinical – Illicit Drugs and Controlled Substances

Detection of THC metabolites in urine by LCMS-8050 based on supported liquid extraction method

Written by:

Abstract

Ang May Yen¹ Udi Jumhawan² Norsalihan Binti Md Amin³ Nurul Syamimi Binti Salleh³ Loo Lai Chin²

¹Customer Support Centre, Shimadzu Malaysia

²Shimadzu (Asia Pacific)

³Department of Pathology, Hospital Kuala Lumpur, Malaysia The growing trend of cannabis legalization as recreational and medicinal drug has prompted authorities to develop cutting-edge technique for detecting cannabinoids especially in biological samples. Its parent drug, Δ9-tetrahydrocannabinol (THC), is not traceable in urine and will be converted into two major conjugated metabolites, 11-hydroxy-Δ9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH). Hydrolysis of glucuronide moiety from THC metabolites can occur through enzymatic reaction and thus clean up are important for sample pretreatment. Supported liquid extraction (SLE) was chosen for effective sample extraction and clean up. Method validation was performed by using LCMS-8050 to measure THC metabolites in urine. The method exhibits 5 ng/mL limit of quantitation (LOQ) for both analytes, well below the requirement for cannabinoids in urine (15 ng/mL).



Effective sample preparation and analysis method are needed for routine cannabis tracing in biological fluids

Keywords: Cannabis, Cannabinoids, Urine, Supported Liquid Extraction

Highlights

- SLE provides effective extraction and clean up of THC metabolites in urine samples after enzymatic hydrolysis
- The developed method meets the UNODC (United Nations Office on Drugs and Crime)'s criteria (linearity, LOQ, recovery, accuracy, precision, specificity/selectivity) for MS-based detection method of THC metabolites in biological specimens
- · LCMS-8050 exhibits remarkable LOQ (5 ng/mL) for detection of THC metabolites in urine sample

Technologies Featured

Shimadzu LC/MS/MS Forensic Toxicology Database





LCMS-8050

1. INTRODUCTION

Despite its role as recreational and medicinal drug, cannabis can potentially lead to dependence and behaviour disturbances affecting a person's daily duties as long-term effects. This concern has prompted authorities to consider advanced technique to trace the track of cannabis intake especially in biological fluids. Urine is among the biological fluid frequently used for routine cannabis tracing.


The parent drug, Δ 9-tetrahydrocannabinol (THC), has a clearance half-life of less than 30 minutes and is not traceable in urine. THC will be converted into its primary metabolites, 11-hydroxy- Δ 9-tetrahydrocannabinol (11-OH-THC) and 11-nor-9-carboxy- Δ 9-tetrahydrocannabinol (THC-COOH), during Phase I metabolism in the liver. These two metabolites are further metabolized to produce glucuronide conjugates of 11-OH-THC and THC-COOH in Phase II metabolism and are excreted in the urine. The glucuronate conjugates typically appear in the urine within 60 minutes but can take up to 4 hours upon ingestion/inhalation. The half-life of THC-COOH is extensive and can be detected in the urine up to 7 days after a single use. It is therefore feasible to trace cannabis intake in the urine sample.

Mass spectrometry has been the gold standard in forensic and clinical analysis for its sensitivity and selectivity. In this report, liquid chromatography mass spectrometry-triple quadrupole system (LCMS-8050) was employed for measuring THC metabolites in urine samples. Enzymatic hydrolysis is essential step to hydrolyze glucuronide moiety from THC metabolites. Consequently, sample cleanup is prerequisite in urine sample preparation. Supported liquid extraction (Biotage ISOLUTE® SLE+) was selected for both extraction and sample clean up.

2. EXPERIMENT

2.1 Experimental Condition

Sample pre-treatment was performed in four steps (hydrolysis, sample loading, elution, reconstitution) by using Biotage ISOLUTE® SLE+ 1 mL cartridge (P/N: 820-0140-C) as shown in Figure 1.



2.2 Analytical Setup

Measurement was carried out on LCMS-8050 with schedule MRM program. Analytical conditions (liquid chromatography, mass spectrometry, and MRM transitions) are described in Table 1 and Table 2.

Column	Biphenyl column (100 mm x 2.1 mm x 2.6 μm)					
Mobile phase	A : 0.2% formic acid in water B : 0.2% formic acid in methanol					
Gradient program	0-1 min (5%B), 1.01-2 min (40%B), 2.01-7 min (100%B), 7.01-10 min (100%B), 10.01-14 min (5%B)					
Flow rate	0-8 min (0.3 mL/min), 8.01-11 min (0.5 mL/min), 11.01-14 min (0.3 mL/min)					
Oven temperature	40°C					
Injection volume	1 μL					
Interface	Heated ESI					
MS mode	MRM, positive mode					
Heat block temperature	400°C					
DL temperature	250°C					
Interface temperature	300°C					
Nebulizing gas	N ₂ , 3 L/min					
Drying gas	N ₂ , 10 L/min					
Heating gas	Zero air, 10 L/min					

Table 1. Analytical conditions for detection of THC metabolites in urine on LCMS-8050

Table 2. MRM transitions of analytes and deuterated IS

Analyte	Transitions	Analyte	Transitions	Analyte	Transitions	Analyte	Transitions
	345.21>327.20*	THC-COOH-D3	348.20>330.15	11-ОН-ТНС	331.23> 193.20*	11-OH-THC-D3	334.30>316.35
тнс-соон	345.21>193.15		348.20>302.15		331.23>201.15		334.30>196.15
	345.21>119.2		348.20>90.90				334.30>201.15

*quantifier ion

3. RESULTS AND DISCUSSION

SLE works based on the ability of analytes to partition from the SLE phase into organic elution solvent. The more hydrophobic the analytes, the more likely analytes will partition. Since THC-COOH and 11-OH-THC are hydrophobic compounds (logP 5.24 and 5.78, respectively), it will be easy to partition these analytes from SLE phase by eluting organic solvent (DCM and IPA). It is therefore, SLE was utilized for sample extraction as well as clean up.

Two to three MRM transitions were used for detection and quantitation of THC metabolites and IS. MRM transitions are based on Shimadzu LC/MS/MS Forensic Toxicology Database (P/N: 225-31175-92) or auto MRM optimization. This ready-to-use database is very effective to reduce running cost and time in forensic or clinical analysis. Auto MRM optimization function is available in LabSolutions software and will assist user to obtain optimized parameters (MRM, collision energy) of each analyte in a single injection.

3.1 Method Validation

There are seven criteria set by UNODC for MS-based detection of THC metabolites in biological specimens: linearity, LOQ (limit of quantitation), extraction recovery, matrix effect, accuracy, precision, and specificity/selectivity.

Linearity and LOQ

Method validation was following the <u>United Nations Office on Drugs and Crime</u> (UNODC) guideline. Calibration curve was constructed based on urine blank matrix containing seven different concentrations (5, 15, 25, 50, 100, 150, 200 ng/mL). Each point was measured in triplicate (n=3). Matrix-based calibration was repeated in six different days to investigate interday repeatability. Linearity of calibration curves was 0.992 or more (Figure 2).

The limit of quantitation (LOQ) is determined based on the lowest concentration at which signal-to-noise ratio is greater than 10 (S/N>10). Injection was repeated six times for LOQ measurement. The LOQ was set at 5 ng/mL and it is well below the requirement for cannabinoids in urine, 15 ng/mL (Figure 3) (<u>Ministry of Health Malaysia</u>).




Figure 2. Representative of matrix-based calibration curve for (A) THC-COOH and (B) 11-OH-THC




Figure 3. Overlay chromatograms of THC-COOH (A) and 11-OH-THC (B) from six injections (n=6) in blank matrix at LOQ (5 ng/mL)

Recovery and matrix effect

Table 3 shows measurement of extraction recovery and matrix effect. Area ratio of analytes in neat and post-extraction spiked blank matrix was compared to determine matrix effect. Matrix effect ranged from 71 to 101%.

Recovery was calculated based on analysis of analytes at three different concentrations. For each concentration, six extract replicates were measured by LCMS-8050. Extraction recovery was observed between 92% to 106%. Taken together, this demonstrates the efficiency of extraction and clean up by SLE method.

Accuracy and precision

Blank urine was spiked with THC metabolites at three different concentrations (15, 50, and 100 ng/mL) and analysed in replicate (intraday repeatability, n=3) on three consecutive days (interday repeatability, n=3) to measure accuracy. Percent accuracies of both metabolites ranged between 90.4 to 106.4% (Table 4). It is in accordance with the guideline stating all results should fall within ±20% of the expected values at lower concentrations and within ±15% at the higher concentrations.

Precision was determined based upon investigation of measurement accuracy and express the variation in terms of the RSD for each concentration. The RSD should be lower than 20% at lower concentrations and better than 15% at higher concentrations. The RSDs of THC-COOH and 11-OH-THC at three different concentrations were observed at 9% or less (Table 4).

Analyte -		Matrix effect (%))		Recovery (%)	
	15 ng/mL	50 ng/mL	100 ng/mL	15 ng/mL	50 ng/mL	100 ng/mL
THC-COOH	101.1	89.8	91.5	104.9	92.0	103.7
11-OH-THC	71.0	87.5	94.6	106.2	99.8	105.2

Table 3. Matrix effect and recovery (n=6)

Table 4. Accuracy and precision (intraday and interday repeatability, n=3)

Analyte		Accuracy (%)			Precision (%)	
	15 ng/mL	50 ng/mL	100 ng/mL	15 ng/mL	50 ng/mL	100 ng/mL
THC-COOH	101.3	92.1	90.4	2.9	9.0	3.1
11-OH-THC	106.4	96.5	97.1	2.5	8.3	1.1

Specificity/Selectivity

Specificity/Selectivity was investigated based on substance interference under the following analysis:

- Standard solutions of drugs of interest (THC metabolites)
- Standard solutions of drugs from other groups such as amphetamine, morphine, diazepam, alprazolam, and dextromethorphan
- Blank urine from five different sources
- · Blank urine spiked with drugs of interest (THC metabolites)

Standard and spiking concentration was carried out at 15 ng/mL.

There was no interfering substances at the retention times of THC metabolites based on injection of spiked blank urine samples (Figure 4). Additionally, retention times of drugs from other groups were distant from retention times of THC metabolites.




Figure 4. Overlay chromatograms of (A & B) 15 ng/mL THC metabolites in neat/solvent (n=3), (C & D) group of other drugs in RT window of THC metabolites (n=3), (E & F) blank urine specimens from five sources (n=5), and (G & H) 15 ng/mL THC metabolites spiked in blank urine specimens (n=3)

4. CONCLUSION

LCMS-based method for detection of THC metabolites, THC-COOH and 11-OH-THC, in urine was validated using Shimadzu LCMS-8050 following guideline from the UNODC. SLE method by using Biotage ISOLUTE® SLE+ was employed to extract and clean up urine samples. The method satisfyingly meets all criteria (calibration linearity, LOQ, recovery, accuracy, precision, specificity/selectivity) set by the UNODC for MS-based detection method of THC metabolites in biological specimens. Owing to remarkable sensitivity of LCMS-8050 and effectiveness of SLE, the method is expected to be a substantial support for routine screening of THC metabolites in biological samples.

5. REFERENCES

- Sharma, P. et al. Chemistry, Metabolism, and Toxicology of Cannabis: Clinical Implications. Iran J Psychiatry. (2012), 7(4): 149-156.
- Drug Testing: Marijuana Δ⁹-Tetrahydrocannabinol (THC). (2020). <u>https://www.mayocliniclabs.com/test-info/drug-book/marijuana.html</u>.
- Biotage ISOLUTE® SLE+ Supported Liquid Extraction Products. (2020). <u>https://www.biotage.com/part-number/820-0140-</u>
 <u>C</u>.
- Shimadzu LC/MS/MS Forensic Toxicology Database.(2020). <u>https://www.shimadzu.com/an/lcms/forensic_toxicology-database/index.html</u>.
- Guidance for the Validation of Analytical Methodology and Calibration of Equipment used for Testing of Illicit Drugs in Seized Materials and Biological Specimens. (2009). <u>https://www.unodc.org/unodc/en/scientists/guidance-for-the-validation-of-analytical-methodology-and-calibration-of-equipment.html</u>.
- Standardization of Drug of Abuse Cut-off in Malaysia, outlined by Ministry of Health in 2017.

READ MORE

LC/MS/MS Forensic Toxicology Database (P/N: 225-31175-92)



Simplified Acquisition and Identification $\dot{\mathbf{v}}$

The Forensic Toxicology Database includes optimized LC-MS/MS data acquisition parameters and a library database to help clinical and forensic researchers build screening and quantitation methods quickly, simplifying method development.

MRM & Spectral Library database contains information on ** more than 2,500 compounds

The spectral library database is built using two separation conditions (ODS and Biphenyl). Both methods have information on clinical and forensic compounds of interest in routine analysis. The ODS method contains information on 1,250 compounds and the Biphenyl method contains 1,281 compounds. Compound datasheet includes monoisotopic mass, RT, CAS number, formula and compound class. This package provides Synchronized Survey Scan parameters (MRM parameters, MRM intensity threshold and triggered product ion scan parameters) optimized for screening analysis.

Enhanced identification by merged spectrum *

Each certified reference material was acquired with three different collision energies to generate an information-rich merged-CE spectrum which can be used in library matching and compound verification. Matching with a merged-CE spectrum library can be a powerful tool to identify compounds with a library score.

Learn More

ISOLUTE® SLE+ Supported Liquid Extraction Products Load-Wait-Elute Sample Preparation

ISOLUTE® SLE+ Supported Liquid Extraction plates and columns are designed to provide stress free extraction of analytes from biological fluids, with high analyte recoveries, and clean, protein and phospholipid free extracts. Methods are easy to develop, and automation is simple.

Efficient Extraction No Emulsion Formation Easy to Automate **Higher Productivity Good Flow Characteristics** Higher Analyte Recoveries

Learn More







Shimadzu (Asia Pacific) Pte. Ltd www.shimadzu.com.sg

For Research Use Only. Not for use in diagnostic procedures. This publication may contain references to products that are not available in your country. Please contact us to check the availability of these products in your country.

The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu.

Shimadzu. Company names, products/service names and logos used in this publication are trademarks and trade names of Shimadzu Corporation, its subsidiaries or its affliates, whether or not they are used with trademark symbol "TM" or "®". Third-party trademarks and trade names may be used in this publication to refer to either the entities or their products/services, whether or not they are used with trademark symbol "TM" or "®". Shimadzu disclaims any proprietary interest in trademarks and trade names other than its own.

The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.